Clinical Trial

Local Therapy for ER/PR-positive Oligometastatic Breast Cancer

Study acronym: LARA
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2022 (before its estimated April 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-01-05; most recent amendment 2022-08-05.
Status change: Not Yet Recruiting → Recruiting 2021-05-03
Trial Details
NCT Number NCT04698252
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Conditions Breast Cancer
Enrollment 74 participants
Start Date 2021-04-01
Primary Completion 2024-04-01 (estimated)
Study Completion 2031-04-01 (estimated)
Updated on ClinicalTrials.gov 2022-08-08